China National Medicines Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Guotao Tian

Amministratore delegato

CN¥2.6m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	2.5yrs
Proprietà del CEO	n/a
Durata media del management	1.9yrs
Durata media del Consiglio di amministrazione	2.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

Nov 12

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28

AMMINISTRATORE DELEGATO

Guotao Tian (53 yo)

2.5yrs

Mandato

CN¥2,550,000

Compensazione

Mr. Guotao Tian is GM & Director of China National Medicines Corporation Ltd. from April 07, 2022.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Guotao Tian	GM & Director	2.5yrs	CN¥2.55m	Nessun dato
Fei Chen	Chief Financial Officer	1.1yrs	CN¥191.30k	Nessun dato
Lichun Luo	Board Secretary	2.5yrs	CN¥1.15m	Nessun dato
Zhang Ting	Deputy Secretary of the Party Committee	no data	CN¥371.90k	Nessun dato

1.9yrs

Durata media

46yo

Età media

Gestione esperta: Il team dirigenziale di 600511 non è considerato esperto (durata media 1.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Guotao Tian	GM & Director	2.6yrs	CN¥2.55m	Nessun dato
Xiuchang Jiang	Chairman	13.7yrs	Nessun dato	Nessun dato
Yong Liu	Director	12.9yrs	Nessun dato	Nessun dato
Jingyun Liu	Chairman of the Supervisory Board	12.9yrs	Nessun dato	Nessun dato
Luwen Shi	Independent Director	2.6yrs	CN¥200.00k	Nessun dato
Xingxi Yu	Independent Director	2.6yrs	CN¥200.00k	Nessun dato
Deyong Wen	Director	5.5yrs	Nessun dato	Nessun dato
Xin Jiang	Director	2.6yrs	CN¥2.55m	Nessun dato
Xiaojuan Li	Director	2.6yrs	Nessun dato	Nessun dato
Kai Lu	Supervisor	2.6yrs	Nessun dato	Nessun dato

2.6yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 600511 non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

China National Medicines Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

China National Medicines Corporation Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

China National Medicines Corporation Ltd. Announces Resignation of Li Hui as A Director, the General Manager, A Member of the Strategy Committee and A Member of the Audit Committee

Recent updates

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings released: EPS: CN¥0.64 (vs CN¥0.63 in 3Q 2023)

China National Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 16%

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: CN¥0.72 (vs CN¥0.76 in 2Q 2023)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

China National Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 22, 2024

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Now 20% undervalued

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Dividend increased to CN¥0.85

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

First quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in 1Q 2023)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China National Medicines Corporation Ltd., Annual General Meeting, Apr 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

China National Medicines (SHSE:600511) Could Easily Take On More Debt

China National Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 21, 2024

Third quarter 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.76 in 3Q 2022)

China National Medicines Corporation Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.65 in 2Q 2022)

Price target increased by 14% to CN¥46.58

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.76 (vs CN¥0.71 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.65 (vs CN¥0.62 in 2Q 2021)

China National Medicines Corporation Ltd.(XSSC:600511) dropped from S&P Global BMI Index

China National Medicines Corporation Ltd.(XSSC:600511) dropped from FTSE All-World Index (USD)

Price target decreased to CN¥39.20

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 23% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.62 (vs CN¥0.51 in 2Q 2020)

Upcoming dividend of CN¥0.55 per share

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.31 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.83 (vs CN¥2.11 in FY 2019)

New 90-day low: CN¥36.33

New 90-day low: CN¥41.32

China National Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

China National Medicines Corporation Ltd. Announces Resignation of Li Hui as A Director, the General Manager, A Member of the Strategy Committee and A Member of the Audit Committee

Investor sentiment deteriorated over the past week

Market bids up stock over the past week

New 90-day high: CN¥50.10

Third quarter earnings released

China National Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Earnings released

New 90-day high - CN¥52.00

China National Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 19, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media